Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 3/20 | 0.54 |
| ▸ | CDK2 | P24941 | 3/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14375845 | 0.85 | RET (0.62) | RPS6KA3PDGFRBRET | |
| SCHEMBL14376389 | 0.84 | KMT2A (0.51) | MEN1KMT2AFLT3CDK2CCNE1 | |
| SCHEMBL14376567 | 0.83 | TLK2 (0.66) | FLT3CDK2CCNE1RPS6KA3PDGFRB | |
| SCHEMBL15896534 | 0.82 | SRC (0.46) | FLT3ALKPDGFRBRETTLK2 | |
| SCHEMBL6001189 | 0.82 | MAPT (0.64) | MEN1KMT2AFLT3ALKRPS6KA3 | |
| SCHEMBL6001190 | 0.82 | MAPT (0.64) | MEN1KMT2AFLT3ALKRPS6KA3 | |
| SCHEMBL14375862 | 0.82 | RET (0.67) | FLT3CDK2CCNE1RPS6KA3PDGFRB | |
| SCHEMBL14375844 | 0.81 | TLK2 (0.52) | FLT3CDK2CCNE1RPS6KA3PDGFRB | |
| SCHEMBL14376386 | 0.81 | MEN1 (0.58) | MEN1KMT2AFLT3CDK2CCNE1 | |
| SCHEMBL15896535 | 0.80 | LRRK2 (0.70) | FLT3CDK2CCNE1ALKRPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2012178015-A2 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140205537-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, MAP2 | MEN1 3448/4885KMT2A 1348/4885FLT3 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.